• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Arch Razi Inst . Design, Synthesis and In Vivo Evaluation of a Candidate Fusion Epitopic Construct Vaccine Based on M2e, HA1, HA2, NA and NP Fragmen

tetano

Editor, Senior Moderator
Arch Razi Inst


. 2024 Aug 1;79(4):849-856.
doi: 10.32592/ARI.2024.79.4.849. eCollection 2024 Aug. Design, Synthesis and In Vivo Evaluation of a Candidate Fusion Epitopic Construct Vaccine Based on M2e, HA1, HA2, NA and NP Fragments of the Highly Pathogenic Avian H5N1 Influenza Virus

A Hamidi[SUP] 1 [/SUP], H Farzin[SUP] 2 [/SUP], A Haghparast[SUP] 1 3 [/SUP]



Affiliations
Abstract

The H5N1 subtype of the influenza virus is highly pathogenic and lethal to humans and animal. The necessity for the development of new vaccines with a broad spectrum of efficacy against this pathogen seems to be very crucial. One highly regarded solution to this problem is to design and production of recombinant vaccines using the conserved peptide of influenza viruses. A search of international databases yielded the peptide sequence of the M2e fragment of H5N1 viruses isolated from Iran, as well as a variety of conserved peptide sequences of fragments of HA1, HA2, NA and NP of other H5N1 viruses. These sequences were obtained for both MHC receptors in mice. Subsequently, these fragments, in conjunction with a PADRE sequence, were connected by bioinformatics to design a fusion epitopic construct. Subsequently, the construct was optimized for expression in E.coli BL21. Following the expression and purifications of the fusion epitopic construct, it was injected subcutaneously (SC) into the hindlimb muscles of 6-8 old week female BALB/c mice. Three weeks following the conclusion of the second immunization, the mice in both immunized and control groups were weighed and checked for any adverse effects at the injection sites. Subsequently, the mice were euthanized and blood was collected from their hearts to determine the total IgG antibody titer before and after immunization by ELISA. No evidence of local inflammation or complications was observed at the SC injection sites until the end of the experiment. Additionally, the autopsy of mice showed no bleeding or lesions in organs, particularly the liver and spleen. The mice exhibited no significant change in weight throughout the immunization period. The total IgG level, as determined by average OD value in the serum of immunized mice, was found to be five times higher (5.881 ng/ml) than that of the control group (1.143 ng/ml). The results demonstrated a highly significant IgG antibody response following SC administration of an immunogenic recombinant peptide in mice.

Keywords: Fusion Epitopic Construct; H5N1; IgG; Influenza Virus; Vaccine.

 
Back
Top Bottom